|
1
|
Yang L: Incidence and mortality of gastric
cancer in China. World J Gastroenterol. 12:17–20. 2006.
|
|
2
|
Sun XD, Mu R, Zhou YS, et al: Analysis of
mortality rate of stomach cancer and its trend in twenty years in
China. Zhonghua Zhong Liu Za Zhi. 26:4–9. 2004.PubMed/NCBI
|
|
3
|
Japanese Research Society for Gastric
Cancer. The General Rules for the Gastric Cancer Study in Surgery
and Pathology. 12th edition. Kanahara Shuppan; Tokyo: 1993
|
|
4
|
Roder JD, Böttcher K, Busch R, et al:
Classification of regional lymph node metastasis from gastric
carcinoma. German Gastric Cancer Study Group. Cancer. 82:621–631.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weber WA and Ott K: Imaging of esophageal
and gastric cancer. Semin Oncol. 31:530–541. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bozzetti F, Marubini E, Bonfanti G, et al:
Subtotal versus total gastrectomy for gastric cancer: five-year
survival rates in a multicenter randomized Italian trial. Italian
Gastrointestinal Tumor Study Group. Ann Surg. 230:170–178.
1999.
|
|
7
|
Hartgrink HH, van de Velde CJ, Putter H,
et al: Extended lymph node dissection for gastric cancer: who may
benefit? Final results of the randomized Dutch Gastric Cancer Group
trial. J Clin Oncol. 22:2069–2077. 2004. View Article : Google Scholar
|
|
8
|
Cuschieri A, Weeden S, Fielding J, et al:
Patient survival after D1 and D2 resections for gastric cancer:
long-term results of the MRC randomized surgical trial. Surgical
Co-operative Group. Br J Cancer. 79:1522–1530. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jansen EP, Boot H, Verheij M and van de
Velde CJ: Optimal locoregional treatment in gastric cancer. J Clin
Oncol. 23:4509–4517. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Van de Velde CJ and Peeters KC: The
gastric cancer treatment controversy. J Clin Oncol. 21:2234–2236.
2003.
|
|
11
|
Degiuli M, Sasako M, Ponti A and Calvo F:
Survival results of a multicentre phase II study to evaluate D2
gastrectomy for gastric cancer. Br J Cancer. 90:1727–1732.
2004.PubMed/NCBI
|
|
12
|
Kodama I, Kofuji K, Yano S, et al: Lymph
node metastasis and lymphadenectomy for carcinoma in the gastric
cardia: clinical experience. Int Surg. 83:205–209. 1998.PubMed/NCBI
|
|
13
|
Yonemura Y, Katayama K, Kamata T, et al:
Surgical treatment of advanced gastric cancer with metastasis in
para-aortic lymph node. Int Surg. 76:222–225. 1991.PubMed/NCBI
|
|
14
|
Qie XD, Chen B, Wang J, et al: Comparison
for treatment experience of gastric cancer between China Medical
University and University of Tokyo – a report of 2438 cases. Med J
Liaoning. 16:238–240. 2002.
|
|
15
|
Wu CW, Hsiung CA, Lo SS, et al: Nodal
dissection for patients with gastric cancer: a randomised
controlled trial. Lancet Oncol. 7:309–315. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sano T, Sasako M, Yamamoto S, et al:
Gastric cancer surgery: morbidity and mortality results from a
prospective randomized controlled trial comparing D2 and extended
para-aortic lymphadenectomy – Japan Clinical Oncology Group study
9501. J Clin Oncol. 22:2767–2773. 2004.PubMed/NCBI
|
|
17
|
Chen L, Zhu ZG, Yan M, et al: Clinical
values of surgical management for stage IV gastric cancer. J
Shanghai Jiaotong University (Medical Science). 27:569–572.
2007.
|
|
18
|
Cunningham D, Allum WH, Stenning SP, et
al: Perioperative chemotherapy versus surgery alone for resectable
gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fang Y, Wang YJ, Li F and Li J:
Oxaliplatin in combination with calcium folinate and fluorouracil
as neoadjuvant chemotherapy in the treatment of advanced gastric
cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 9:510–512.
2006.PubMed/NCBI
|
|
20
|
Yang J and Wang ZG: The combination of
docetaxel, cisplatin, fluorouracil and leucovorin (CF) as
neoadjuvant chemotherapy for the treatment of non-resectable
advanced gastric cancer. China Oncol. 16:346–350. 2006.
|
|
21
|
Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang
DW and Zhang RG: Randomized clinical trial on the combination of
preoperative irradiation and surgery in the treatment of
adenocarcinoma of the gastric cardia (AGC) – report on 370
patients. Int J Radiat Oncol Biol Phys. 42:929–934. 1998.
|
|
22
|
The Gastrointestinal Tumor Study Group.
Controlled trial of adjuvant chemotherapy following curative
resection for gastric cancer. Cancer. 49:1116–1122. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Higgins GA, Amadeo JH, Smith DE, Humphrey
EW and Keehn RJ: Efficacy of prolonged intermittent therapy with
combined 5-FU and methyl-CCNU following resection for gastric
carcinoma. A Veterans Administration Surgical Oncology Group
report. Cancer. 52:1105–1112. 1983. View Article : Google Scholar
|
|
24
|
Hermans J, Bonenkamp JJ, Boon MC, et al:
Adjuvant therapy after curative resection for gastric cancer:
meta-analysis of randomized trials. J Clin Oncol. 11:1441–1447.
1993.PubMed/NCBI
|
|
25
|
Earle CC and Maroun JA: Adjuvant
chemotherapy after curative resection for gastric cancer in
non-Asian patients: revisiting a meta-analysis of randomised
trials. Eur J Cancer. 35:1059–1064. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Janunger KG, Hafström L and Glimelius B:
Chemotherapy in gastric cancer: a review and updated meta-analysis.
Eur J Surg. 168:597–608. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mari E, Floriani I, Tinazzi A, et al:
Efficacy of adjuvant chemotherapy after curative resection for
gastric cancer: a meta-analysis of published randomised trials. A
study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi
dell’ Apparato Digerente). Ann Oncol. 11:837–843. 2000.
|
|
28
|
Sakuramoto S, Sasako M, Yamaguchi T, et
al: Adjuvant chemotherapy for gastric cancer with S-1, an oral
fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Macdonald JS, Smalley SR, Benedetti J, et
al: Chemoradiotherapy after surgery compared with surgery alone for
adenocarcinoma of the stomach or gastroesophageal junction. N Engl
J Med. 345:725–730. 2001. View Article : Google Scholar
|
|
30
|
Lim DH, Kim DY, Kang MK, et al: Patterns
of failure in gastric carcinoma after D2 gastrectomy and
chemoradiotherapy: a radiation oncologist’s view. Br J Cancer.
91:11–17. 2004.PubMed/NCBI
|
|
31
|
Kang Y, Kang WK, Shin DB, et al:
Randomized phase III trial of capecitabine/cisplatin (XP) vs.
continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in
patients (pts) with advanced gastric cancer (AGC): efficacy and
safety results. Proc Am Soc Clin Oncol. 24:abs. LBA4018. 2006.
|
|
32
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
et al; V325 Study Group. Phase III study of docetaxel and cisplatin
plus fluorouracil compared with cisplatin and fluorouracil as
first-line therapy for advanced gastric cancer: a report of the
V325 Study Group. J Clin Oncol. 24:4991–4997. 2006.PubMed/NCBI
|
|
33
|
Cunningham D, Starling N, Rao S, et al;
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom. Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin ML, Chen Q, Cheng FQ, et al:
Oxaliplatin (OXA) in combination with LV5FU2 in Chinese patients
with advanced gastric cancer (AGC). Proc Am Soc Clin Oncol. 21:abs.
558. 2002.
|
|
35
|
Zhu X, Leaw J, Gu W, et al: Phase II
clinical trial of advanced and metastatic gastric cancer based on
continuous infusion of 5-fluorouracil combined with epirubicin and
oxaliplatin. J Cancer Res Clin Oncol. 134:929–936. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cunningham D, Humblet Y, Siena S, et al:
Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hurwitz HI, Fehrenbacher L, Hainsworth JD,
et al: Bevacizumab in combination with fluorouracil and leucovorin:
an active regimen for first-line metastatic colorectal cancer. J
Clin Oncol. 23:3502–3508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shah MA, Ramanathan RK, Ilson DH, et al:
Multicenter phase II study of irinotecan, cisplatin and bevacizumab
in patients with metastatic gastric or gastroesophageal junction
adenocarcinoma. J Clin Oncol. 24:5201–5206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pinto C, Di Fabio F, Siena S, et al: Phase
II study of cetuximab in combination with FOLFIRI in patients with
untreated advanced gastric or gastroesophageal junction
adenocarcinoma (FOLCETUX study). Ann Oncol. 18:510–517. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Doi T, Koizumi W, Siena S, et al:
Efficacy, tolerability and pharmacokinetics of gefitnib (ZD1839) in
pretreated patients with metastatic gastric cancer. Proc Am Soc
Clin Oncol. 22:abs. 1036. 2003.
|
|
41
|
Dragovich T, McCoy S, Fenoglio-Preiser CM,
et al: Phase II trial of erlotinib in gastroesophageal junction and
gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 24:4922–4927.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ling Y, Yang Y, Lu N, et al: Endostar, a
novel recombinant human endostatin, exerts antiangiogenic effect
via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of
endothelial cells. Biochem Biophys Res Commun. 361:79–84. 2007.
View Article : Google Scholar
|
|
43
|
Jiang HQ, Li YL and Zou J: Effect of
recombinant human endostatin on endometriosis in mice. Chin Med J
(Engl). 120:1241–1246. 2007.PubMed/NCBI
|
|
44
|
Zhou ZW, Wan DS, Wang GQ, et al:
Inhibitory effect of angiogenesis inhibitor YH-16 on liver
metastases from colorectal cancer. Ai Zheng. 25:818–822.
2006.PubMed/NCBI
|
|
45
|
Wang JW, Sun Y, Liu YY, et al: Results of
randomized, multicenter, double-blind phase III trial of
rh-endostatin (YH-16) in treatment of advanced non-small cell lung
cancer patients. Chin J Lung Cancer. 8:283–290. 2005.PubMed/NCBI
|
|
46
|
Lieto E, Ferraraccio F, Orditura M, et al:
Expression of vascular endothelial growth factor (VEGF) and
epidermal growth factor receptor (EGFR) is an independent
prognostic indicator of worse outcome in gastric cancer patients.
Ann Surg Oncol. 15:69–79. 2008. View Article : Google Scholar
|
|
47
|
Lievre A, Bachet JB, Le Corre D, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lievre A, Bachet JB, Boige V, et al: KRAS
mutations as an independent prognostic factor in patients with
advanced colorectal cancer treated with cetuximab. J Clin Oncol.
26:374–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Blanke CD, Joensuu H, Demetri GD, et al:
Outcome of advanced gastrointestinal stromal tumor (GIST) patients
treated with imatinib mesylate: Four-year follow-up of a phase II
randomized trial. Proc Am Soc Clin Oncol. 24:abs. 7. 2006.
|
|
50
|
Innocenti F, Undevia SD, Iyer L, et al:
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene
predict the risk of severe neutropenia of irinotecan. J Clin Oncol.
22:1382–1388. 2004. View Article : Google Scholar : PubMed/NCBI
|
